Am J Psychiatry 161:780-796, May 2004
© 2004 American Psychiatric Association
Pharmacogenetics of Psychotropic Drug Response
Anil K. Malhotra, M.D.,
Greer M. Murphy, Jr., M.D., Ph.D., and
James L. Kennedy, M.D.
OBJECTIVE: Molecular genetic approaches provide a novel method of dissecting the heterogeneity of psychotropic drug response. These pharmacogenetic strategies offer the prospect of identifying biological predictors of psychotropic drug response and could provide the means of determining the molecular substrates of drug efficacy and drug-induced adverse events. METHOD: The authors discuss methods issues in executing pharmacogenetic studies, review the first generation of pharmacogenetic studies of psychotropic drug response, and consider future directions for this rapidly evolving field. RESULTS: Pharmacogenetics has been most commonly used in studies of antipsychotic drug efficacy, antidepressant drug response, and drug-induced adverse effects. Data from antipsychotic drug studies indicate that polymorphisms within the serotonin 2A and dopamine receptor 2 genes may influence drug efficacy in schizophrenia. Moreover, a growing body of data suggests a relationship between the serotonin transporter gene and clinical effects of the selective serotonin reuptake inhibitors used to treat depression. A significant relationship between genetic variation in the cytochrome P450 system and drug-induced adverse effects may exist for certain medications. Finally, a number of independent studies point to a significant effect of a dopamine D3 receptor polymorphism on susceptibility to tardive dyskinesia. CONCLUSIONS: Initial research into the pharmacogenetics of psychotropic drug response suggests that specific genes may influence phenotypes associated with psychotropic drug administration. These results remain preliminary and will require further replication and validation. New developments in molecular biology, human genomic information, statistical methods, and bioinformatics are ongoing and could pave the way for the next generation of pharmacogenetic studies in psychiatry.
This article has been cited by other articles:
|
|
|
|
 
C. Barbui MD, T. A. Furukawa MD, and A. Cipriani MD
Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials
Can. Med. Assoc. J.,
January 29, 2008;
178(3):
296 - 305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Hwang, T. Shinkai, V. De Luca, Xingqun Ni, S. G. Potkin, J. A. Lieberman, H. Y. MeLtzer, and J. L. Kennedy
Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response
J Psychopharmacol,
September 1, 2007;
21(7):
718 - 727.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Yoshida, H. Higuchi, M. Kamata, H. Takahashi, K. Inoue, T. Suzuki, K. Itoh, and N. Ozaki
The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine
J Psychopharmacol,
August 1, 2007;
21(6):
650 - 656.
[Abstract]
[PDF]
|
|
|
|
|
|
|
X.-Z. Hu, A. J. Rush, D. Charney, A. F. Wilson, A. J. M. Sorant, G. J. Papanicolaou, M. Fava, M. H. Trivedi, S. R. Wisniewski, G. Laje, et al.
Association Between a Functional Serotonin Transporter Promoter Polymorphism and Citalopram Treatment in Adult Outpatients With Major Depression
Arch Gen Psychiatry,
July 1, 2007;
64(7):
783 - 792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Burger and J. Neeleman
A glossary on psychiatric epidemiology
J. Epidemiol. Community Health,
March 1, 2007;
61(3):
185 - 189.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Rey
The Interface of Multiculturalism and Psychopharmacology
Journal of Pharmacy Practice,
December 1, 2006;
19(6):
379 - 385.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. W. Roberts, T. D. Warner, K. G. Hammond, and L. B. Dunn
Assessments by Patients With Schizophrenia and Psychiatrists of Relative Risk of Research Procedures
Psychiatr Serv,
November 1, 2006;
57(11):
1629 - 1635.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. K. Plesniccar, B. Zalar, K. Breskvar, and V. Dolzzan
The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment
J Psychopharmacol,
November 1, 2006;
20(6):
829 - 833.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. P. Reynolds, B. Arranz, L. A. Templeman, S. Fertuzinhos, and L. San
Effect of 5-HT1A Receptor Gene Polymorphism on Negative and Depressive Symptom Response to Antipsychotic Treatment of Drug-Naive Psychotic Patients
Am J Psychiatry,
October 1, 2006;
163(10):
1826 - 1829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Kane
Tardive Dyskinesia Circa 2006
Am J Psychiatry,
August 1, 2006;
163(8):
1316 - 1318.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Murphy Jr
Application of microarray technology in psychotropic drug trials.
J Psychopharmacol,
July 1, 2006;
20(4 Suppl):
72 - 78.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Lencz, D. G. Robinson, K. Xu,, J. Ekholm, S. Sevy, H. Gunduz-Bruce, M. G. Woerner, J. M. Kane, D. Goldman, and A. K. Malhotra
DRD2 Promoter Region Variation as a Predictor of Sustained Response to Antipsychotic Medication in First-Episode Schizophrenia Patients
Am J Psychiatry,
March 1, 2006;
163(3):
529 - 531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B Dunn, P. J Candilis, and L. W. Roberts
Emerging Empirical Evidence on the Ethics of Schizophrenia Research
Schizophr Bull,
January 1, 2006;
32(1):
47 - 68.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Fleck and E. Horwath
Pharmacologic Management of Difficult-to-Treat Depression in Clinical Practice
Psychiatr Serv,
August 1, 2005;
56(8):
1005 - 1011.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Yoshida, H. Takahashi, H. Higuchi, M. Kamata, K.-i. Ito, K. Sato, S. Naito, T. Shimizu, K. Itoh, K. Inoue, et al.
Prediction of Antidepressant Response to Milnacipran by Norepinephrine Transporter Gene Polymorphisms
Am J Psychiatry,
September 1, 2004;
161(9):
1575 - 1580.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Reviews of Note
Journal Watch Psychiatry,
August 4, 2004;
2004(804):
6 - 6.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2004
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
